On May 15, 2015, the FDA warned consumers that the SGLT2 inhibitor class of type 2 diabetes medications has been linked to many reports of a dangerous condition called diabetic ketoacidosis, or ketosis. Ketoacidosis is a severe condition normally only seen in patients with type 1 diabetes whereby acid in a person’s blood rises to extremely high levels. Symptoms of ketoacidosis include difficulty breathing, nausea, vomiting, abdominal pain, fatigue. If left untreated, ketoacidosis can cause permanent damage to the patient and may lead to death. The FDA has cautioned people taking any of the following sglt2 medications are at risk of developing Ketoacidosis:
Invokana has also been linked to an immediate increase in heart attack and stroke among patients who begin taking the drug. In fact, research done to gain FDA approval of Invokana suggests that patients are at highest risk for an adverse cardiac event within the first 30 days of taking the medication. Rather than warn doctors or patients of this risk, Invokana has chosen to conceal this side effect in an attempt to sell its product and gain a larger market share over the other drugs in this class of medicines.
If you or a loved one has taken any of the SGLT2 inhibitor class of type 2 diabetes medications and suffered ketoacidosis or an adverse cardiac event such as stroke or heart attack, please contact our office to discuss the possibility of filing a lawsuit against the manufacturers of these drugs.